Zacks Investment Research
21 Nov 2025, 14:06 UTC · 51w ago
Why 2025 is a Dynamic and Transformative Year for Collegium
Impact · against what's priced in
Collegium Pharmaceutical (COLL) appears fundamentally bullish due to aggressive capital returns and commercial expansion for Jornay PM. While other peer pharmaceutical companies are mentioned, the material updates are concentrated in COLL's operational growth and shareholder yield.
- COLL+0.60
No priced-in read yet





